Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Transcept Pharmaceuticals to Report Third Quarter 2011 Financial Results and Host Conference Call on November 10, 2011

November 2, 2011

POINT RICHMOND, Calif., Nov. 2, 2011 /PRNewswire/ — Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Thursday, November 10, 2011 at 4:30 p.m. Eastern Time to discuss its third quarter 2011 financial results. The conference call will follow the release of the Transcept third quarter 2011 financial results after the close of market that day.

(Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO )


    Conference Call Information
      Date: Thursday, November 10, 2011
      Time: 4:30 p.m. ET
      Dial-in (U.S.): 877-638-4558
      Dial-in (International): 914-495-8537

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through December 31, 2011.

A telephone replay of the conference call will be available shortly after the conclusion of the call through November 17, 2011. The replay telephone number is 855-859-2056 (U.S.) or 404-537-3406 (International), replay passcode: 24717067.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Transcept is developing Intermezzo® (zolpidem tartrate sublingual tablet) as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Transcept is also developing TO-2061, a low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with approved first-line pharmacotherapy. For further information, please visit the Transcept website at: www.transcept.com.

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.


Source: PR Newswire